Immunome, Inc.IMNMNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank37
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P37
Within normal range
vs 3Y Ago
-2.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-24.81%
Q3 202517.25%
Q2 202511.31%
Q1 2025-30.59%
Q4 2024-21.65%
Q3 2024-38.71%
Q2 2024-93.05%
Q1 202425.12%
Q4 2023-105.87%
Q3 2023-43.97%
Q2 2023-124.96%
Q1 2023456.28%
Q4 202210.78%
Q3 20228.01%
Q2 2022-28.96%
Q1 20226.41%
Q4 2021-63.49%
Q3 2021-11.26%
Q2 2021-5.13%
Q1 202141.62%
Q4 2020-130.32%
Q3 2020-44.05%
Q2 202013.12%
Q1 202019.92%
Q4 2019-6.44%
Q3 2019-5.76%
Q2 20190.00%
Q1 20190.00%